Advertisement

Drugs

, Volume 76, Issue 2, pp 255–262 | Cite as

Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia

  • Lesley J. ScottEmail author
Adis Drug Evaluation

Abstract

Hypophosphatasia (HPP) is a rare inheritable disease that results from loss-of-function mutations in the ALPL gene encoding tissue-nonspecific alkaline phosphatase (TNSALP). Therapeutic options for treating the underlying pathophysiology of the disease have been lacking, with the mainstay of treatment being management of symptoms and supportive care. HPP is associated with significant morbidity and mortality in paediatric patients, with mortality rates as high as 100 % in perinatal-onset HPP and 50 % in infantile-onset HPP. Subcutaneous asfotase alfa (Strensiq®), a first-in-class bone-targeted human recombinant TNSALP replacement therapy, is approved in the EU for long-term therapy in patients with paediatric-onset HPP to treat bone manifestations of the disease. In noncomparative clinical trials in infants and children with paediatric-onset HPP, asfotase alfa rapidly improved radiographically-assessed rickets severity scores at 24 weeks (primary timepoint) as reflected in improvements in bone mineralization, with these benefits sustained after more than 3 years of treatment. Furthermore, patients typically experienced improvements in respiratory function, gross motor function, fine motor function, cognitive development, muscle strength (normalization) and ability to perform activities of daily living, and catch-up height-gain. In life-threatening perinatal and infantile HPP, asfotase alfa also improved overall survival. Asfotase alfa was generally well tolerated in clinical trials, with relatively few patients discontinuing treatment and most treatment-related adverse events being of mild to moderate intensity. Thus, subcutaneous asfotase alfa is a valuable emerging therapy for the treatment of bone manifestations in patients with paediatric-onset HPP.

Keywords

Craniosynostosis Injection Site Reaction Hypophosphatasia Child Health Assessment Questionnaire Skeletal Manifestation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

During the peer review process, the manufacturer of asfotase alfa was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Bianchi ML. Hypophosphatasia: an overview of the disease and its treatment. Osteoporos Int. 2015;26:2743–57.PubMedCrossRefGoogle Scholar
  2. 2.
    Millán JL, Whyte MP. Alkaline phosphatase and hypophosphatasia. Calcif Tissue Int. 2015. doi: 10.1007/s00223-015-0079-1.PubMedGoogle Scholar
  3. 3.
    Wenkert D, McAlister WH, Coburn SP, et al. Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). J Bone Miner Metab. 2011;26(10):2389–98.CrossRefGoogle Scholar
  4. 4.
    Weber T, Sawyer E, Moseley S, et al. Burden of disease in children with hypophosphatasia: results from patient-reported surveys [abstract no. P119]. In: 7th International Conference on Children’s Bone Health; 2015.Google Scholar
  5. 5.
    Whyte M, Leung E, Wilcox W, et al. Hypophosphatasia: a retrospective natural history study of the severe perinatal and infantile forms [abstract no. 200]. In: Joint meeting of the Pediatric Academic Societies (PAS) and the Asian Society for Pediatric Research; 2014.Google Scholar
  6. 6.
    Weber T, Sawyer E, Moseley S, et al. Fracture and surgical burden in pediatric and adult patients with hypophosphatasia: results from patient-reported outcome surveys [abstract no. 516]. In: American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress; 2015.Google Scholar
  7. 7.
    Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(Suppl 2):380–8.PubMedGoogle Scholar
  8. 8.
    Weber T, Sawyer E, Moseley S, et al. Burden of disease in adult patients with hypophosphatasia: results from patient-reported outcome surveys [abstract no. FRI-240]. In: 97th Endocrine Society Annual Meeting; 2015.Google Scholar
  9. 9.
    Fraser D. Hypophosphatasia. Am J Med. 1957;22(5):730–46.PubMedCrossRefGoogle Scholar
  10. 10.
    Greenberg CR, Taylor CLD, Haworth JC, et al. A homoallelic Gly317 → Asp mutation in APL causes the perinatal (lethal) form of hypophosphatasia in Canadian Mennonites. Genomics. 1993;17(1):215–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Leung ECW, Mhanni AA, Reed M, et al. Outcome in perinatal hypophosphatasia in Manitoba Mennonites: a retrospective cohort analysis. JIMD Rep. 2013;11:73–8.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Mornet E. Hypophosphatasia. Orphanet J Rare Dis. 2007;2(40).Google Scholar
  13. 13.
    European Medicines Agency. Strensiq 40 mg/mL solution for injection, Strensiq 100 mg/mL solution for injection: summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 20 July 2015.
  14. 14.
    Millán JL, Plotkin H. Hypophosphatasia: pathophysiology and treatment. Actual Osteol. 2012;8(3):164–82.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366(10):904–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Nishioka T, Tomatsu S, Gutierrez MA, et al. Enhancement of drug delivery to bone:characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab. 2006;88(3):244–55.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Yadav MC, de Oliveira RC, Foster BL, et al. Enzyme replacement prevents enamel defects in hypophosphatasia mice. J Bone Miner Res. 2012;27(8):1722–34.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Yadav MC, Lemire I, Leonard P, et al. Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. Bone. 2011;49(2):250–6.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Millán JL, Narisawa S, Lemire I, et al. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res. 2008;23(6):777–87.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    McKee MD, Nakano Y, Masica DL, et al. Enzyme replacement therapy prevents dental defects in a model of hypophosphatasia. J Dent Res. 2011;90(4):470–6.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    European Medicines Agency. CHMP assessment report: Strensiq. 2015. http://www.ema.europa.eu/. Accessed 20 July 2015.
  22. 22.
    Rodriguez E, Bober M, Davey L, et al. Respiratory mechanics in an infant with perinatal lethal hypophosphatasia treated with human recombinant enzyme replacement therapy. Pediatr Pulmonol. 2012;47(9):917–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Hiremath S, Devendra Kumar VK, Padidela R, et al. Neonatal hypophosphatasia: a rare disorder and new treatment [abstract no. PF.60 ]. Arch Dis Child Fetal Neonatal Ed. 2013;98(Suppl 1):A20–1.Google Scholar
  24. 24.
    Whyte MP, Rockman-Greenberg C, Ozono K, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab. 2015. doi: 10.1210/jc.2015-3462.PubMedGoogle Scholar
  25. 25.
    Whyte M, Simmons J, Bishop N, et al. Asfotase alfa: sustained efficacy and tolerability in infants and young children with life-threatening hypophosphatasia [abstract no. 69 plus poster]. In: Joint Meeting of the Pediatric Academic Societies (PAS) and the Asian Society for Pediatric Research; 2014.Google Scholar
  26. 26.
    Greenberg CR, Vockley J, Harmatz P, et al. Asfotase alfa improves skeletal mineralization and respiratory function in infants and young children with hypophosphatasia: results from up to 12 months ‘ treatment [abstract no. FC20-1488]. Horm Res. 2013;80(Suppl 1):70.Google Scholar
  27. 27.
    Hofmann C, Rockman-Greenberg C, Harmatz P, et al. Improvement in bone manifestations and respiratory status in infants and young children with HPP treated with asfotase alfa: an update on the ENB-010-10 trial [abstract]. Bone Abstr. 2015;4:OC18.Google Scholar
  28. 28.
    Madson KL, Rockman-Greenberg C, Whyte MP, et al. Asfotase alfa: long-term safety and efficacy in children with hypophosphatasia [abstract no. 3808.202]. In: Pediatric Academic Societies Annual Meeting; 2014.Google Scholar
  29. 29.
    Madson K, Rockman-Greenberg C, Melian A, et al. Asfotase alfa: sustained improvements in hypophosphatasia-related rickets, physical function, and pain during 3 years of treatment for severely affected children [abstract no. 1081]. In: 36th Annual Meeting of the American Society for Bone and Mineral Research; 2014.Google Scholar
  30. 30.
    Bishop N, Simmons J, Lutz R, et al. Hypophosphatasia: gross motor function and height improvement in infants and young children treated with asfotase alfa for up to 3 years [abstract no. FC2.2]. Horm Res. Paediatr. 2014;82(Suppl 1):29.Google Scholar
  31. 31.
    Phillips D, Hamilton K, Moseley S, et al. Improved activities of daily living and physical function, with decreased pain, in children with hypophosphatasia treated for three years with asfotase alfa: results from the Childhood Health Assessment Questionnaire and the Pediatric Outcomes Data Collection Instrument [abstract no. FRI-224]. Endocr Rev. 2015;36(2).Google Scholar
  32. 32.
    Phillips D, Hamilton K, Moseley S, et al. Significantly improved muscle strength, running speed, and agility in children with hypophosphatasia treated with asfotase alfa [abstract no. OC4.3 plus oral presentation]. In: 4th Joint Meeting of the European Calcified Tissue Society (ECTS) and the International Bone and Mineral Society (IBMS); 2015.Google Scholar
  33. 33.
    European Medicines Agency. Public summary for opinion on orphan designation: recombinant human tissue nonspecific alkaline phosphatase-Fc-deca-aspartate fusion protein for the treatment of hypophosphatasia. 2008. http://www.ema.europa.eu/. Accessed 27 July 2015.
  34. 34.
    Kishnani P, Langman C, Linglart A, et al. A longitudinal, prospective, long-term registry of patients with hypophosphatasia [abstract no. P154]. In: 7th International Conference on Children’s Bone Health; 2015.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations